Results suggest olanzapine should be a standard to reduce chemotherapy-induced nausea and vomiting

Kenrick Ng, Consultant in Medical Oncology at Barts Health NHS Trust shared a post on X by Yüksel Ürün:

“Evidence for using olanzapine, an effective and cost friendly antiemetic, is robust but very underused in U.K.

We have also demonstrated how using olanzapine in a steroid-sparing protocol reduces rates of neutropenic sepsis in GCT patients”

Neutropenic sepsis rates in patients receiving bleomycin, etoposide and cisplatin chemotherapy using olanzapine and reduced doses of dexamethasone compared to a standard antiemetic regimen

Authors: Ernese Gjafa, Kenrick Ng, Tami Grunewald, Myria Galazi, Erik Skyllberg, Peter Wilson, Constantine Alifrangis, Jonathan Shamash

Quoting Yüksel Ürün’s post:

“In a phase 3 trial (Again and again…) with 560 patients, adding olanzapine to dexamethasone, palonosetron, and aprepitant increased complete response rates from 82% to 91%.

Results suggest olanzapine should be a standard to reduce chemotherapy-induced nausea and vomiting (CINV).”

Source: Kenrick Ng/X and Yüksel Ürün/X